In this study, we demonstrated that B. fragilis treatment prevented the development of acute dextran sulfate sodium (DSS)-induced colitis by partly inhibiting IL-1β and C-C chemokine receptor 5 (CCR5) expression. The gene discussed is CCR5; the disease is colitis.